Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1011 of 6351
-
Can a smart dosing tool prevent heart transplant rejection in children?
Disease control CompletedImmunosuppressive therapy is required to prevent organ rejection, however, dosing of immunosuppressive agents is complicated by patient-specific differences impacting the body's absorption and elimination of these agents. The goal of this research proposal is to clinically valida…
Sponsor: University of Utah • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti programmed cell death protein 1(anti-PD-1) antibody pembrolizumab.…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Old drug, new hope: ATRA combo targets tough pancreatic cancer
Disease control OngoingThis is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.
Phase 2 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a single gene fix help stop bleeding in hemophilia a?
Disease control OngoingThis is a Phase I study. This research study is being conducted to find new ways to treat severe hemophilia A. This study is a gene therapy study. Gene therapy is an experimental way to introduce, into a person's cells, specific genetic material. A gene can be delivered/introduce…
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for chinese patients with Hard-to-Treat blood cancers
Disease control OngoingThis is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can dropping one blood thinner cut bleeding without raising heart risks?
Disease control CompletedAtrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy, and thus are widely accepted in clinical practice. …
Phase 4 • Sponsor: Yonsei University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough rectal cancers
Disease control CompletedDetermine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered virus joins forces with immunotherapy to fight resistant cancers
Disease control OngoingThis is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, an…
Phase 2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill shows promise in slowing advanced breast cancer
Disease control OngoingThis study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Pandemic pregnancy: tracking COVID's impact on mothers and babies
Knowledge-focused OngoingProspective nationwide cohort study of pregnant women enrolled early in gestation and followed for Covid-19 exposure and infection, with follow up of obstetrical outcomes and infant development through the first year of life.
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
New cocktail aims to shrink deadly brain tumors
Disease control CompletedIn this study, the investigators propose to combine retifanlimab with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The investigators hypothesize that this combination provides a powerful synergy between RT an…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Cheap drug combo may tame tough anemia
Disease control CancelledAutoimmune anemia (AIA), including autoimmune hemolytic anemia (AIHA), EVENs' syndrome (ES), acquired pure red aplastic anemia (PRCA), is a kind of anemia disease mediated by autoimmunity, which can be primary or secondary to other diseases including autoimmune disease, malignant…
Phase 4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Radiation boost may extend life in lung cancer that has spread to a few spots
Disease control Recruiting nowStandard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial
Phase 3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:46 UTC
-
Can mentorship and skills training boost resilience in HIV-Positive teen moms?
Disease control CompletedThe overall objective of the Pregnant and Parenting Girls (P2G) Program evaluation was to measure resilience among pregnant and parenting girls (18 years and above) living with HIV in Lusaka who have benefitted from the comprehensive package of interventions under P2G program. Th…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Experimental drug leronlimab tested in 484 severe COVID-19 patients
Disease control CompletedThe purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
Phase 2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for inoperable brain tumors: radioactive drug trial launches
Disease control Recruiting nowThis phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a simple wash catch ovarian cancer before it spreads?
Diagnosis Recruiting nowThe study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors …
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 17:54 UTC
-
Immunotherapy combo aims to shrink advanced liver tumors
Disease control CompletedThis is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the …
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a steroid combo be the key to fighting sepsis? large trial seeks answers
Disease control Recruiting nowMain objective and primary endpoint: To compare the effect hydrocortisone plus fludrocortisone vs. placebo on a composite of death or persistent organ dysfunction - defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors - assesse…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Immunotherapy plus radiation may keep endometrial cancer from returning
Disease control OngoingThis phase III trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed stage I-II endometrial cancer. Immunotherapy with monoc…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC